Search results for "RADIOTHERAPY"

showing 10 items of 473 documents

Non-Hodgkin B-cell lymphoma involving the palate.

2018

Oncologymedicine.medical_specialtyLymphoma B-CellPalatal Neoplasmsbusiness.industryTreatment outcomeRemission InductionPalatal NeoplasmsChemoradiotherapymedicine.diseaseRemission inductionTreatment OutcomeOncologyInternal medicinemedicineBiomarkers TumorHumansFemalePalatal NeoplasmB-cell lymphomabusinessChemoradiotherapyHumanAgedThe Lancet. Oncology
researchProduct

The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.

2008

Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen.ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 …

Oncologymedicine.medical_specialtyRadiation-Sensitizing AgentsCell SurvivalApoptosisDeoxycytidine03 medical and health sciences0302 clinical medicineFludarabine monophosphateInternal medicineCell Line TumormedicineCarcinomaHumansRadiology Nuclear Medicine and imaging030304 developmental biology0303 health sciencesRadiological and Ultrasound Technologybusiness.industryHead and neck cancermedicine.diseaseGemcitabineGemcitabine3. Good healthFludarabineSquamous carcinomaApoptosis030220 oncology & carcinogenesisCarcinoma Squamous CellbusinessVidarabine PhosphateChemoradiotherapymedicine.drugInternational journal of radiation biology
researchProduct

Endometrial and Cervical Cancers

2021

Uterine corpus and cervical cancers are showing, in the last decades, increasing incidence and mortality in industrialized and developing countries, respectively; on the other hand, innovative therapeutic strategies are emerging for the management of advanced gynecological malignancies. Risk factors and predisposing conditions are widely and continually studied; thus, prevention, through lifestyle correction and/or validated screening tests, could represent a promising tool to diagnose earlier and reduce mortality of uterine cancers. Herein, management of endometrial and cervical tumors from diagnosis to commonly applied standards of care and experimental frontiers are depicted so as to pro…

Oncologymedicine.medical_specialtyScreening testbusiness.industryIncidence (epidemiology)Endometriummedicine.diseasemedicine.anatomical_structureUterine corpusUterine cancerInternal medicinemedicinePersonalized medicinebusinessCervixChemoradiotherapy
researchProduct

Association de radiothérapie externe et de curiethérapie pour les cancers de la prostate

2017

International audience; Brachytherapy as sole treatment is standard of care for D’Amico classification low-risk prostate cancer. For intermediate and high-risk patients, brachytherapy can be associated to external beam radiation therapy to better take into account the risk of extracapsular effraction and/or seminal vesicle involvement. Three randomized studies have shown that this association increases freedom from relapse survival compared to exclusive external beam radiation therapy. This benefit is not shown for overall survival. The addition of a hormonal therapy to this association is most likely mandatory for high-risk patients, and needs to be confirmed for intermediate risk patients…

Oncologymedicine.medical_specialtyStandard of caremedicine.medical_treatmentBrachytherapyBrachytherapy[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesProstate cancer0302 clinical medicineProstateInternal medicineMedicineRadiology Nuclear Medicine and imagingBoostRadiothérapieCancerGynecologyRadiotherapybusiness.industryGenitourinary systemProstateCancermedicine.disease3. Good healthRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCuriethérapieHormonal therapybusiness
researchProduct

Cancer of the Esophagus

2021

In 2015 esophageal cancer (OC) was globally the 11th most common cancer with 483,000 new cases and the 7th most common cause of cancer-related deaths, with 439,000 deaths. Esophageal cancer is a highly lethal disease of older age, sixth to seventh decades, associated with a remarkable decline in health-related quality of life, high mortality, and poor prognosis with an overall 5-year survival no greater than 20%. The two major histological types, squamous cell carcinoma (SCC) and adenocarcinoma (ADC), while sharing the esophageal site, can be considered like two different neoplastic diseases as they differ in their epidemiology, risk factors, pathogenesis, and treatment. Other malignancies …

Oncologymedicine.medical_specialtybusiness.industryCancerEsophageal cancermedicine.diseasemedicine.anatomical_structureInternal medicineCarcinosarcomamedicineCarcinomaAdenocarcinomaSarcomaEsophagusbusinessChemoradiotherapy
researchProduct

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month…

2021

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCheckmateCancerHematologymedicine.diseaseGastroesophageal JunctionOncologyInternal medicineMedicineNivolumabbusinessAdjuvantNeoadjuvant chemoradiotherapyMonth follow upAnnals of Oncology
researchProduct

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT pr…

2019

Summary Background There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter. In the CeTeG/NOA-09 trial, we aimed to further investigate the effect of lomustine-temozolomide therapy in the setting of a randomised phase 3 trial. Methods In this open-label, randomised, phase 3 trial, we enrolled patients from 17 German university hospitals who were aged 18–70 years, with newly diagnosed glioblastoma with methylated MGMT promoter, and a Karnofsky Performance …

Oncologymedicine.medical_specialtyeducation.field_of_studyTemozolomidebusiness.industryPopulationHazard ratioMedizinGeneral MedicineLomustine030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawConcomitantInternal medicinemedicineClinical endpoint030212 general & internal medicineeducationbusinessChemoradiotherapymedicine.drugThe Lancet
researchProduct

Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary to…

2015

To investigate the feasibility and tolerance in the use of adjuvant intensity modulated radiation therapy (IMRT) and simultaneous integrated boost in patients with a diagnosis of breast cancer after breast-conserving surgery.Between September 2011 to February 2013, 112 women with a diagnosis of early breast cancer (T1-2, N0-1, M0) were treated with IMRT and simultaneous integrated boost after breast-conserving surgery in our institution. A dose of 50Gy in 25 fractions was prescribed to the whole breast and an additional dose of radiation was prescribed on the tumour bed. A dose prescription of 60Gy in 25 fractions to the tumour bed was used in patients with negative margins after surgery, w…

Oncologymedicine.medical_treatmentSegmentalMastectomy SegmentalSeverity of Illness IndexBreast cancerNuclear Medicine and ImagingDuctalIntensity-Modulated80 and overBreastMastectomyAdjuvantEarly breast cancerAged 80 and overCarcinoma Ductal BreastSIBRadiotherapy DosageMiddle AgedOncologyBreast cancer; IMRT; SIB; Toxicity; Adult; Aged; Aged 80 and over; Breast Neoplasms; Carcinoma Ductal Breast; Carcinoma Lobular; Esthetics; Feasibility Studies; Female; Follow-Up Studies; Humans; Mastectomy Segmental; Middle Aged; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Adjuvant; Severity of Illness Index; Radiotherapy Intensity-Modulated; Oncology; Radiology Nuclear Medicine and ImagingToxicityFemaleRadiologyRadiodermatitisRadiologyAdjuvantSimultaneous integrated boostAdultmedicine.medical_specialtyEstheticsBreast NeoplasmsLobularBreast cancerInternal medicineSeverity of illnessmedicineHumansRadiology Nuclear Medicine and imagingIMRTAgedToxicityRadiotherapybusiness.industryCarcinomaIntensity-modulated radiation therapymedicine.diseaseAcute toxicityBreast cancer; IMRT; SIB; Toxicity; Oncology; Radiology Nuclear Medicine and ImagingCarcinoma LobularFeasibility StudiesRadiotherapy AdjuvantRadiotherapy Intensity-ModulatedbusinessFollow-Up Studies
researchProduct

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

2005

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role …

Oncologystage IIIA-N2medicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentDocetaxelNSCLCDeoxycytidinemolecular markers analysisCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineStage (cooking)Lung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryInduction chemotherapyHematologymedicine.diseaseearly stageGemcitabineRadiation therapyneoadjuvant radiotherapyOncologyTolerabilityDocetaxelChemotherapy AdjuvantRadiotherapy AdjuvantTaxoidsCisplatinbusinessmedicine.drugneoadjuvant chemotherapy
researchProduct

Dentin-pulp complex reactions in conventional and radiation-related caries: A comparative study

2019

Background Radiation-related caries (RRC) is one of the most significant oral toxicities of head and neck radiotherapy (HNRT); however, the potential of radiation to directly cause harmful dentin and pulpal effects and impair response to caries progression is controversial. Material and Methods Therefore, the aim of this study was to characterize the reactions of the dentin-pulp complex in teeth affected by RRC. Patients and methods: Twenty-two carious teeth extracted from 22 head and neck cancer (HNC) patients were divided into control (conventional caries; n=11) and irradiated (RRC; n=11) groups and paired matched by dental homology, clinical patterns of caries progression following the P…

Oral Medicine and Pathologybusiness.industrymedicine.medical_treatmentResearchHead and neck cancerDentistryReactionary dentinmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Radiation therapyDemineralizationstomatognathic diseasesmedicine.anatomical_structureHead and neck radiotherapystomatognathic systemCarious teethUNESCO::CIENCIAS MÉDICASDentinmedicinePulp (tooth)businessGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct